Cytek Biosciences, Inc. — fact timeline

Cytek Biosciences, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm at the 2026-06-10 meeting.

“3. Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 110,533,253 479,883 148,354 —”

Cytek Biosciences, Inc. shareholders approved Advisory vote on executive compensation at the 2026-06-10 meeting.

“2. Executive Compensation. On a non-binding, advisory basis, the compensation paid to the Company’s named executive officers for the year ended December 31, 2025 was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 84,794,380 677,861 21,212 25,668,037”

Cytek Biosciences, Inc. shareholders approved Election of Class II Directors at the 2026-06-10 meeting.

“1. Election of Class II Directors. Each of the following nominees was elected to serve as a Class II director, to hold office until the Company’s 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal, based on the following results of voting: Nominee Votes For Votes Withheld Broker Non-Votes Vera Imper, Ph.D. 64,769,976 20,723,477 25,668,037 Glenn P. Muir 79,599,103 5,894,350 25,668,037 Ming Yan, Ph.D. 76,741,063 8,752,390 25,668,037”

Philippe Busque resigned as Senior Vice President, Global Sales and Services at Cytek Biosciences, Inc..

“On May 27, 2026, Philippe Busque, Ph.D. submitted his resignation from his position as the Senior Vice President, Global Sales and Services of Cytek Biosciences, Inc. (the “Company”), effective as of June 5, 2026, to pursue another career opportunity.”

Cytek Biosciences, Inc. reported first quarter ended March 31, 2026 results: revenue $44.1 million, net income Net loss in the first quarter of 2026 was $18.9 million. Guidance reaffirmed.

“cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights • Total revenue for the first quarter of 2026 was $44.1 million, representing a 6% increase compared to the first quarter of 2025 • Service revenue for the first quarter of 2026 was $15.4 million, representing a 15% increase compared to”

Paul Christopher Williams resigned as Chief Operating Officer at Cytek Biosciences, Inc..

“On September 9, 2024, Paul Christopher Williams submitted his resignation from his position as the Chief Operating Officer of Cytek Biosciences, Inc. (the “Company”), effective as of September 27, 2024, to pursue another career opportunity.”

Cytek Biosciences, Inc. reported the quarter ended March 31, 2024 results: revenue $44.9 million, net income $6.2 million. Guidance reaffirmed.

“(Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights • Total revenue was $44.9 million, representing a 21% increase over the corresponding period of 2023 • Organic revenue was $37.3 million, representing an increase of 11% compared to the first quarter of 2023 •”

William McCombe was appointed as Chief Financial Officer at Cytek Biosciences, Inc..

“On March 19, 2024, the Board of Directors of the Company announced the appointment of William (“Bill”) McCombe as the Chief Financial Officer of the Company, effective March 18, 2024.”

Patrik Jeanmonod changed role as Chief Financial Officer at Cytek Biosciences, Inc..

“Effective as of March 17, 2024, Patrik Jeanmonod stepped down from his position as the Chief Financial Officer of Cytek Biosciences, Inc. (the “Company”) to serve as the Company’s Head of Corporate Development Analytics.”

Cytek Biosciences, Inc. reported year ended December 31, 2023 results: revenue $193.4 million, net income $11.3 million.

“the fourth quarter of 2022. Fourth quarter revenue from the product lines acquired from Luminex Corporation (“Luminex”) on February 28, 2023 was $9.8 million • Total revenue was $193.4 million, or $194.1 million on a non-GAAP constant currency basis, for the full year 2023, representing 18% and 13% increases, respectively, over the full year 2022. • Organic revenue was”

Cytek Biosciences, Inc. reported fourth quarter ended December 31, 2023 results: revenue $58.6 million, net income $6.3 million.

“CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2023. Recent Highlights • Total revenue was $58.6 million, or $58.2 million on a non-GAAP constant currency basis, for the fourth quarter of 2023, representing 21% and 14% increases, respectively, over the corresponding period of 2022 •”

Cytek Biosciences, Inc. reported preliminary financial results for the full year ended December 31, 2023.

“Cytek expects its full year revenue for 2023 to be near the high end of the company’s most recent revenue guidance range of $188 million to $192 million”

Cytek Biosciences, Inc. reported the third quarter ended September 30, 2023 results: revenue $48.0 million.

“Total revenue for the third quarter of 2023 was $48.0 million”

Cytek Biosciences, Inc. reported the second quarter ended June 30, 2023 results: revenue $49.7 million, net income $4.4 million. Guidance reaffirmed.

“(“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2023. Recent Highlights • Total revenue was $49.7 million, representing 24% growth over the second quarter of 2022 • Total revenue on a non-GAAP constant currency basis was $50.0 million • Organic revenue for Cytek’s existing product”

Cytek Biosciences, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-14 meeting.

“4. Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 84,894,550 11,239 310,182 —”

Cytek Biosciences, Inc. shareholders approved Frequency of Stockholder Vote on Executive Compensation (advisory vote) at the 2023-06-14 meeting.

“3. Frequency of Stockholder Vote on Executive Compensation. On an advisory basis, a one-year frequency of future advisory votes on the compensation of the Company’s named executive officers was approved based on the following results of voting: One Year Two Years Three Years Abstentions Broker Non-Votes 58,649,562 109,046 165,909 686,914 25,604,540”

Cytek Biosciences, Inc. shareholders approved Executive Compensation (advisory vote) at the 2023-06-14 meeting.

“2. Executive Compensation. On an advisory basis, compensation paid to the Company’s named executive officers for the year ended December 31, 2022 was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 57,420,396 1,390,622 800,413 25,604,540”

Cytek Biosciences, Inc. shareholders approved Election of Class II Directors at the 2023-06-14 meeting.

“1. Election of Class II Directors. Each of the following nominees was elected to serve as a Class II director, to hold office until the Company’s 2026 annual meeting of stockholders or until his or her successor has been duly elected and qualified or his or her earlier death, resignation or removal: Nominee Votes For Votes Withheld Broker Non-Votes Jack Ball 55,857,084 3,754,347 25,604,540 Vera Imper, Ph.D. 49,090,622 10,520,809 25,604,540 Ming Yan, Ph.D. 56,925,027 2,686,404 25,604,540”

Cytek Biosciences, Inc. reported full year 2023 results: revenue $205 million to $220 million. Guidance lowered.

“As a result of macro-economic uncertainties causing longer sales cycles, Cytek Biosciences has revised its full year 2023 revenue outlook and now expects total revenue to be in the range of $205 million to $220 million, representing growth of 25% to 34% over full year 2022.”

Cytek Biosciences, Inc. reported the first quarter ended March 31, 2023 results: revenue $37.1 million, net income $6.8 million.

“First Quarter Highlights • Total revenue was $37.1 million, or $38.1 million on a constant currency basis, representing 6% and 9% increases respectively, over the first quarter of 2022. • Organic revenue for Cytek’s existing product portfolio was $33.7 million in the first quarter of 2023, representing a decline of 4% compared to the first quarter of 2022 • Revenue from the product lines acquired from Luminex Corporation, which closed February 28, 2023, was $3.4 million • Net loss was $6.8 million and adjusted EBITDA was $(2.5) million for the first quarter of 2023”

Cytek Biosciences, Inc. reported full year 2023 results: revenue $225 million to $235 million. Guidance initiated.

“Cytek Biosciences expects full year 2023 revenue in the range of $225 million to $235 million, representing growth of 37% to 43% over full year 2022.”

Cytek Biosciences, Inc. reported the year ended December 31, 2022 results: revenue $164.0 million, net income $2.5 million.

“Total revenue for the year ended December 31, 2022 was $164.0 million, a 28% increase over the year ended December 31, 2021. On a constant currency basis, total revenue for the full year 2022 was $171.8 million, a 34% increase over the full year 2021. Gross profit was $101.0 million for the year ended December 31, 2022, an increase of 28% compared to a gross profit of $79.1 million in the year ended December 31, 2021. Gross profit margin was 62% in the year ended December 31, 2022 compared to 62% in the year ended December 31, 2021. Adjusted gross profit margin in the year ended December 31, 2022 was 63% compared to 63% in the year ended December 31, 2021, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles. Operating expenses were $102.8 million for the year ended December 31, 2022, a 47% increase from $70.0 million in the year ended December 31, 2021. The increase was primarily due to expenses to support continued growth of the bus”

Cytek Biosciences, Inc. reported the fourth quarter of 2022 results: revenue $48.3 million, net income $3.7 million.

“Total revenue for the fourth quarter of 2022 was $48.3 million, a 24% increase over the fourth quarter of 2021, with continued demand across the full portfolio of Cytek’s offerings. On a constant currency basis, total revenue for the fourth quarter of 2022 was $51.2 million, a 32% increase over the fourth quarter of 2021. Gross profit was $29.4 million for the fourth quarter of 2022, an increase of 24% compared to a gross profit of $23.6 million in the fourth quarter of 2021. Gross profit margin was 61% in the fourth quarter of 2022 compared to 61% in the fourth quarter of 2021. Adjusted gross profit margin in the fourth quarter of 2022 was 62% compared to 63% in the fourth quarter of 2021, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles. Operating expenses were $29.3 million for the fourth quarter of 2022, a 31% increase from $22.3 million in the fourth quarter of 2021. The increase was primarily due to expenses to support conti”

Cytek Biosciences, Inc. completed an acquisition involving Luminex Corporation for approximately $46.5 million in cash (closed 2023-02-28).

“under the Purchase Agreement. Pursuant to the Purchase Agreement, as consideration for the FCI Acquisition, the Company paid an aggregate purchase price of approximately $46.5 million in cash, subject to certain customary adjustments at closing, and assumed certain liabilities of the Business. The foregoing description of the FCI Acquisition and the Purchase”

Cytek Biosciences, Inc. entered into Asset Purchase Agreement with Luminex Corporation valued at approximately $46.5 million in cash (effective 2023-02-13).

“On February 13, 2023, Cytek Biosciences, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Luminex Corporation (“Luminex”), pursuant to which the Company agreed to acquire certain assets relating to the business of manufacturing, marketing, selling, servicing and maintaining Amnis-, CellStream-, Guava- and Muse-branded instruments, and flow cytometry reagent products and services of Luminex (the “Business”) for a purchase price of approximately $46.5 million in cash.”

Cytek Biosciences, Inc. reported the third quarter ended September 30, 2022 results: revenue $40.5 million, net income $1.6 million. Guidance reaffirmed.

“Total revenue was $40.5 million for the third quarter, representing an 18% increase over the corresponding quarter of 2021”

Chris Williams was appointed as Chief Operating Officer at Cytek Biosciences, Inc..

“the Board of Directors (the “Board”) of Cytek Biosciences, Inc. (the “Company”) announced the appointment of Chris Williams as the Company’s Chief Operating Officer, effective October 31, 2022.”

Dr. Vera Imper was appointed as Class II director at Cytek Biosciences, Inc..

“the Board unanimously voted to (i) increase the number of authorized directors on the Board from six to seven and (ii) appoint Dr. Vera Imper to serve as a Class II director of the Company, effective December 31, 2021”